Tilak Mallik, MD
Endocrinology, Diabetes & Metabolism · Marrero, LANPI 1437160959
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 55 manufacturers reported payments, led by Amgen at 43.3% of the total. Reporting peaked in 2019 at $34,085 and has fallen 95.3% since, to $1,600 in 2025.
Across 973 payments — averaging $52.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$22K
- Merck$8K
- Novo Nordisk$4K
- Corcept Therapeutics$4K
- Boehringer Ingelheim$1K
- AbbVie$1K
- plus $11K from 49 others
Across 56 payments — averaging $1165.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$63K
- Shire North American Group Inc$2K
- Sanofi US Services Inc.$350
What the payments were for
- Consulting fees$4,5009%
- Speaking & faculty fees$24,73048%
- Travel & lodging$3,2386%
- Food & beverage$18,84937%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,358 in reported general payments places this provider in the 85th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 290 | $450,276 |
| JardianceEmpagliflozin | 221 | $219,077 |
| TrulicityDulaglutide | 124 | $209,547 |
| ProliaDenosumab | 106 | $182,292 |
| MounjaroTirzepatide | 111 | $174,219 |
| Tresiba Flextouch U-200Insulin Degludec | 94 | $87,901 |
| Tresiba Flextouch U-100Insulin Degludec | 122 | $69,181 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 76 | $65,233 |
| TradjentaLinagliptin | 59 | $51,308 |
| FarxigaDapagliflozin Propanediol | 46 | $49,905 |
| RybelsusSemaglutide | 18 | $48,421 |
| SynthroidLevothyroxine Sodium | 434 | $42,564 |
| QutenzaCapsaicin/Skin Cleanser | 12 | $40,631 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $38,341 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $34,503 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $4,452 | $545,662389 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,111 | $407,021321 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $1,395 | $284,269300 claims |
| AmgenProlia | $22,262 | $182,292106 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $962 | $73,221121 claims |
| MerckJanuvia, Janumet, Janumet Xr | $7,559 | $71,88190 claims |
| AstraZenecaFarxiga | $918 | $49,90546 claims |
| AbbVieSynthroid | $1,140 | $42,564434 claims |
| GRT US Holding, Inc.Qutenza | $62 | $40,63112 claims |
| BayerKerendia | $678 | $19,22717 claims |
| Amneal Pharmaceuticals LLCUnithroid | $424 | $17,784132 claims |
| Johnson & JohnsonInvokana | $43 | $14,91012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Marrero
- Marideli ScanlanMarrero$444K
- Alejandra Riera GonzalezMarrero$7K
- Sarah KeslerMarrero$5K
- Amy VarugheseMarrero$3K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Justin FontenotLafayette$397K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.